Omaha, Neb.-based medical device company Bot Image has received FDA clearance for its ProstatID technology, a prostate cancer detection tool that combines MRI technology and artificial intelligence.
ProstatID recognizes and measures the volume of the prostate gland from MRIs to detect signs of cancer. The technology can then assign a cancer probability score to each image, according to the Aug. 8 Bot Image news release.
"Prostate cancer screening and detection methods adoption has changed little over the past 30 years, despite the mountain of evidence pointing to the efficacy of superior technologies and the futility of the old methods," company founder and CEO Dr. Randall W. Jones said. "Sadly, this has resulted in the unnecessary and premature deaths of countless numbers of men in the US alone. ProstatID represents an exciting step in the fight to save lives."